Background Statin (HMG-CoA reductase inhibitor) therapy is the mainstay dyslipidemia treatment and reduces the risk of a cardiovascular (CV) event (CVE) by up to 35%. However, adherence to statin therapy is poor. One reason patients discontinue statin therapy is musculoskeletal pain and the associated risk of rhabdomyolysis. Research is ongoing to develop a pharmacogenomics (PGx) test for statin-induced myopathy as an alternative to the current diagnosis method, which relies on creatine kinase levels. The potential economic value of a PGx test for statin-induced myopathy is unknown. Methods We developed a lifetime discrete event simulation (DES) model for patients 65 years of age initiating a statin after a first CVE consisting of either an acute myocardial infarction (AMI) or a stroke. The model evaluates the potential economic value of a hypothetical PGx test for diagnosing statin-induced myopathy. We have assessed the model over the spectrum of test sensitivity and specificity parameters. Results Our model showed that a strategy with a perfect PGx test had an incremental cost-utility ratio of 4273 Canadian dollars ($Can) per quality-adjusted life year (QALY). The probabilistic sensitivity analysis shows that when the payer willingness-to-pay per QALY reaches $Can12,000, the PGx strategy is favored in 90% of the model simulations. Conclusion We found that a strategy favoring patients staying on statin therapy is cost effective even if patients maintained on statin are at risk of rhabdomyolysis. Our results are explained by the fact that statins are highly effective in reducing the CV risk in patients at high CV risk, and this benefit largely outweighs the risk of rhabdomyolysis.
Abstract Background Statin (HMG-CoA reductase inhibitor) therapy is the mainstay dyslipidemia treatment and reduces the risk of a cardiovascular (CV) event (CVE) by up to 35%. However, adherence to statin therapy is poor. One reason patients discontinue statin therapy is musculoskeletal pain and the associated risk of rhabdomyolysis. Research is ongoing to develop a pharmacogenomics (PGx) test for statin-induced myopathy as an alternative to the current diagnosis method, which relies on creatine kinase levels. The potential economic value of a PGx test for statin-induced myopathy is unknown. Methods We developed a lifetime discrete event simulation (DES) model for patients 65 years of age initiating a statin after a first CVE consisting of either an acute myocardial infarction (AMI) or a stroke. The model evaluates the potential economic value of a hypothetical PGx test for diagnosing statin-induced myopathy. We have assessed the model over the spectrum of test sensitivity and specificity parameters.
Results Our model showed that a strategy with a perfect PGx test had an incremental cost-utility ratio of 4273 Canadian dollars ($Can) per quality-adjusted life year (QALY) . The probabilistic sensitivity analysis shows that when the payer willingness-to-pay per QALY reaches $Can12,000, the PGx strategy is favored in 90% of the model simulations.
Conclusion We found that a strategy favoring patients staying on statin therapy is cost effective even if patients maintained on statin are at risk of rhabdomyolysis. Our results are explained by the fact that statins are highly effective in reducing the CV risk in patients at high CV risk, and this benefit largely outweighs the risk of rhabdomyolysis.
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Introduction
It is estimated that 13.3 million Canadians have elevated cholesterol levels (i.e., dyslipidemia 1 ) [1] . Statins (HMGCoA reductase inhibitors) are the mainstay treatment for dyslipidemia and effectively reduce the risk of a cardiovascular (CV) event (CVE) by 25% to 35% [2] . In Canada, the estimated direct cost of cholesterol-lowering medications, with statins being the most commonly prescribed drugs in this class, is 1.6 billion Canadian dollars ($Can) annually [3] .
Statin-induced myopathy is a potential adverse effect of statin therapy that often manifests as musculoskeletal pain (MSP) and may lead to treatment interruption [4] . Myopathy is a broad term used to describe muscle toxicity, which is classified into three levels of severity: (1) myalgia: muscle symptoms, such as ache or weakness with normal creatine kinase (CK) levels; (2) myositis: muscle symptoms with elevated CK levels; and (3) rhabdomyolysis: muscle symptoms with CK elevation (typically[ 10 times the upper limit of normal value) and creatinine elevation [5] . Rhabdomyolysis can lead to complications such as renal damage and, in rare cases, death [6, 7] . The incidence of suspected statin-induced myopathy is 5-10% in randomized clinical studies [7, 8] , and as high as 25% in some observational studies [8] [9] [10] .
Statin-induced myopathy is currently diagnosed using CK tests, which have limited diagnostic capacity due to poor internal validity as elevated CK levels may be caused by a variety of factors other than statin therapy [5, 6, 11, 12] . A pharmacogenomics (PGx) test could serve as a diagnostic tool in patients who have initiated statin therapy and suffer from MSP, and could provide physicians with an accurate diagnostic tool. More importantly, this tool would help physicians guide patients with MSP unrelated to statin use to continue statin therapy to prevent future CVEs.
The guidelines and recommendations regarding statin intolerance involve various strategies specific to patients, including stop and re-challenge, changes in molecule, changes in dosage, and ensuring patients fully understand the long-term benefits of statin therapy [13] [14] [15] . Nevertheless, patients may decide not to follow their physician's prescribing recommendations without their physician's knowledge. As the Canadian Cardiovascular Society Dyslipidemia Guidelines point out, ''statin intolerance and adverse effects remain of great interest in the media and in lay materials readily available to patients.'' [16] The potential economic value of a PGx test for the diagnosis of statin-induced myopathy is unknown [17] . Although such a PGx test for statin-induced myopathy does not yet exist, it is the target of ongoing research [17, 18] . The current economic evaluation is an early assessment of some of the co-authors' (JCT, MPD, and AD) PGx test development effort funded by Genome Canada and Genome Quebec (grant number 4530) [19, 20] . Our previous economic model assessed the potential economic value of this theoretical PGx test using a Markov health state model [21] . The model results showed that a totally imperfect PGx test (false positive rate [FPR] and false negative rate [FNR] of 100%) would still be cost effective with an incremental cost-utility ratio (ICUR) well below the commonly referred to willingness-to-pay (WTP) threshold. We revisited the economic evaluation of the theoretical PGx test [21] using a discrete event simulation (DES) method.
The main difference between the two models is how the models are informed on the survival of events. The Markov health state model uses point estimate transition probabilities obtained from published cost-effectiveness models.
The DES uses estimated survival curve functions obtained from published Kaplan-Meier graphics converted to numerical values. The other differences in the DES model are consequences of the change in risk of events from the representative population captured by the survival curves. The DES population captured by the survival curves is representative of patients 65 years of age. In the Markov model, we used the statin efficacy estimates from the subgroup of patients\ 60 years of age, whereas for the DES we used those in the subgroup of patients C 60 years of age from 4S (the Scandinavian Simvastatin Survival Study) [22] . As the efficacy of statins for the subgroup of patients who are C 60 years of age is lower, this reduces the benefit of the PGx test, which aims to maintain patients on statin therapy.
Method

Economic Evaluation
We developed a DES model to assess the cost-effectiveness of a hypothetical PGx test to identify statin-induced myopathy in high-risk, secondary prevention CV patients experiencing MSP. Although Markov modelling is the most common approach in pharmacoeconomics, DES modelling is an alternative approach that has been used in various healthcare problems over the past 30 years [23] . DES modelling offers several advantages over a Markovian approach: simulation and retention of patient history, CV risk patient profile update after each event, and time flexibility (compared to a Markov approach which relies on a fixed cycle length) [24] . The Electronic Supplementary Material Appendix provides detailed information on the estimation of the time-to-event functions as well as information on the software used for this study.
To assess the economic value of the PGx test across the full range of the test performance outcomes, from perfectly accurate to totally inaccurate, we varied the FNR and FPR. The FNR (FPR) is the proportion of test results in the presence (absence) of statin-induced myopathy that would falsely indicate the absence (presence) of statin-induced myopathy. We developed the model with a lifetime horizon from the perspective of a public payer in Canada. All costs were inflated to 2016 Canadian dollar values.
Model Assumptions
The model comprises two strategies to diagnose statin-induced myopathy: with or without the PGx test. We assumed patients who have MSP after initiating a statin for secondary CV prevention ask their physicians about statininduced myopathy. The decision regarding whether to maintain patients on statin therapy depends on the (1) diagnostic tool (CK vs. PGx test); (2) physician prescribing recommendation; and (3) patient's decision to follow their physician's recommendation.
Aligned with the co-authors' current research on the PGx test previously described, we assumed physicians will not require the PGx test for patients who present with rhabdomyolysis, which is easily diagnosed with the current diagnosis tools [9, 21, 25] . Patients diagnosed with rhabdomyolysis will have their statin therapy interrupted permanently.
In the environment without the PGx test, we assumed patients with MSP will interrupt their statin therapy based on either the physician recommendation to discontinue or a fear of rhabdomyolysis despite a physician recommendation to continue therapy. This assumption is relaxed in sensitivity analyses.
In the PGx test environment, we assumed physicians would require a test for all patients presenting with MSP. Thus, public payers incur the PGx test cost only for these patients. Physicians would base their prescribing recommendation on the PGx test result. Figure 1 shows the DES model structure. The model was designed to simulate the lifetime histories of patients 65 years of age initiating a statin for secondary prevention after surviving a first CVE consisting of either a stroke or an acute myocardial infarction (AMI). Each patient is initially assigned a sequence of events based on their characteristics. The model first checks whether each simulated patient has an MSP event occurring before any mortality events. Patients not satisfying this condition are rejected from the model. Patients continuing in the model are duplicated to each strategy (with or without PGx test). The model then processes the sequence of events by jumping forward to the first event time. The CV history profile of the simulated patient is updated as well as the CVE counter, statin status, quality-adjusted life years (QALYs), and costs incurred from time zero until the event time. Each patient time-to-event sequence is updated to account for a change in their CV risk profile. Thus, for patients experiencing a CVE, the model updates the time-to-event sequence by randomly assigning new event times which correspond to patients' current CV history. The model evaluates whether the patient died; otherwise, the model reprocesses the sequence of events until the patient dies.
Model Structure
Model Cardiovascular Events
Patients enter the model after having survived a first CVE consisting of either a first stroke or a first AMI. A stroke survivor could experience stroke recurrences or have a first AMI and AMI recurrences. Similarly, an AMI survivor could experience AMI recurrences or have a first stroke and stroke recurrences. The CVE risks are modelled using estimated survival curves found in the literature [26] [27] [28] . Detailed information on the time-to-event functions are presented in the Electronic Supplementary Material Appendix.
Model Mortality
For each CVE in the model simulation, patients are at risk of 30-day mortality [29, 30] . Table 1 presents the 30-day CVE mortality probabilities used in the base case, deterministic sensitivity analysis (DSA), and probabilistic sensitivity analysis (PSA). We assumed that patients who have a third CVE, excluding their initial event, die on the day of the event. Patients surviving beyond the 30-day mortality are subject to mortality based on their updated CV risk profile using published all-cause mortality survival curves [26, 31, 32] . In addition, patients may die from all-cause mortality from the general population based on sex-specific Canadian life tables [33] . Detailed information on the timeto-event functions are presented in the Electronic Supplementary Material Appendix.
Statin Efficacy
Simulated patients entered the model initiating a high-dose statin. To capture the CVE and mortality risk reduction associated with statin therapy, we based the statin efficacy on the relative risk reduction of treatment compared with placebo for the subgroup of patients aged C 60 years of age from Pedersen et al. [22] . We applied the relative risk [51] to the estimated survival curves. Table 1 presents the model statin risk reduction parameters used in the base case, DSA, and PSA.
Statin Interruption
In the model, we only considered statin interruption related to MSP and that a fraction of patients presenting to their physician will have statin-induced myopathy. Patients interrupting statin therapy for any other reasons would be similar in each group and would not contribute to the incremental analysis. We assumed that statin interruption is permanent.
Statin interruption changes the CV risk profiles of patients as they no longer benefit from the CV risk reduction associated with statin therapy. Thus, the model reassesses the complete sequence of events after statin interruption based on the new CV risk profile. The naïve method to update the sequence of events would be to draw new event times from the survival curves. However, this approach would lead to cases where patients would live longer, even though they no longer benefit from the statin CV risk reduction. Therefore, we updated event times considering that: The Electronic Supplementary Material Appendix provides further details on the method for updating CV-related event times.
Costs
Canadian cost data presented in Table 1 were obtained from previously published cost studies, cost-effectiveness studies, and public governmental sources. Cost data were inflated to 2016 Canadian dollars using the all-components consumer price index table from Statistics Canada [34] . To account for the skewness observed in healthcare costs data, we set the low and high scenarios to 75 and 200%, respectively [35] . For physician visits, low and high values were based on the minimal and maximal values from the RAMQ Physician Code Book [36] . The daily statin cost was based on the daily cost of generic simvastatin 80 mg from the prescription list price in Québec [37] . We assumed a PGx test cost of $Can250. Table 1 presents the health utility values used in the model for the base case, DSA, and PSA. The CV utility and disutility data were obtained from Sullivan et al. [38] . We did not identify data for the disutility related to myopathy and rhabdomyolysis. We therefore assumed that the myopathy-related disutility was similar to the disutility in patients going from mild to moderate fibromyalgia reported by Hauber et al. [39] . For rhabdomyolysis, we assumed the disutility was equivalent to the relative change in utility between patients with an estimated glomerular filtration rate (eGFR) C 60 and those patients with an eGFR\ 15 or on dialysis reported by Gorodetskaya et al. [40] .
Health Utilities
Base-Case Analysis
The DES model simulates a cohort of 60,000 patients. The subset of patients satisfying the MSP condition (see Sect. 2.1.2) are duplicated between the two model strategies.
For the strategy with the PGx test, we assumed a 'perfect world', defined as follows: (1) the PGx test is perfect (FNR = 0% and FPR = 0%); (2) physicians will recommend to either continue or interrupt statins based on the PGx test result; and (3) patients will adhere to their physician recommendation regardless of whether they still have MSP.
For the strategy without the PGx test, we assumed that physicians and/or patients are risk-averse in the presence of MSP and interrupt the statin therapy out of fear of developing rhabdomyolysis. This situation is equivalent to that of a PGx test with FNR = 0% and FPR = 100%. This would also be the case when patients ignore physician recommendations to try alternative statin treatment patterns (e.g., molecule switch, dose reduction, stop and rechallenge).
Sensitivity Analyses
We carried out sensitivity analyses to assess parameter uncertainty. For each scenario of the DSA, 60,000 patients are simulated similar to the base case. For the PSA, we chose to reduce the number of patients simulated to 5000 as the computer time for running the base model with 60,000 patients is close to 30 min. Instead, we opted for replicating the model with 1000 simulations. For each sensitivity analysis, the model parameters are varied as specified in Table 1 . The DSA results are presented in a tornado diagram while the PSA results are summarized in a cost-effectiveness acceptability curve (CEAC).
Scenario Analyses
In the scenario analyses, we re-evaluated the base-case model varying the FNR and FPR parameters from 0 to 100%. As we previously argued, this scenario analysis is an important aspect of the present economic evaluation for three reasons [21] . First, the model evaluates a hypothetical situation, and thus we do not know the 'real-life' test performance parameters. Second, evaluating the complete range of test efficacy parameters provides public payers with a comprehensive picture of the economic value of the PGx test, especially when we use a broader interpretation of test parameters including cases where physicians and/or patients do not completely adhere to the test results. Third, if the economic evaluation is made sufficiently early in the development process, it allows test developers to understand the optimal combination of test parameters from an economic perspective.
The scenario analyses are presented using an incremental net monetary benefit (INMB) method as opposed to the ICUR used in Mitchell et al. [21] . Although the INMB method requires the payer's WTP threshold to be specified, we believe this method allows us to explore the impact of the payer's WTP on the PGx value.
Results
Base-Case Analysis
The main results for the base case are shown in Table 2 . Overall, about half (48.3%) of the 60,000 patients created were retained in the model and assigned to each strategy. The ICUR was $Can4273 per QALY for the strategy with the PGx test versus without the test. For a PGx test cost of $Can250, assuming an arbitrary WTP of $Can10,000 per QALY, the INMB was $Can4962. Table 3 presents the proportion of patients with none to three CVEs during the model simulation. Seventy-six percent of patients with the PGx strategy had no additional CVEs, a 2.8% reduction compared with the strategy without the PGx test. Fewer patients with the PGx strategy experienced one CVE (-2.3%) or two CVEs (-0.6%) than with the strategy without the PGx test. Although, there was a negligible increase in the proportion of patients who had three CVEs with the PGx strategy versus without the PGx strategy (4.2 vs. 4.1%), this may be caused by patients living longer with the PGx strategy (78 vs. 76 years, respectively).
Sensitivity Analyses
We assessed the robustness of the INMB model base case of $Can4962 in a DSA, assuming a payer's WTP of $Can10,000 per QALY (see Fig. 2 ). The four parameters most sensitive to change were the discount rate, efficacy of statin therapy in reducing all-cause mortality, overall statin efficacy, and annual cost of managing a long-term CVE survivor. The INMB values in the DSA ranged from $Can481 to $Can16,197. The maximal INMB value Figure 3 shows the CEAC comparing the two strategies. The PSA consisted of repeating 1000 random evaluations of the model with 5000 patients for each simulation. The PSA simulations favored the strategy without the PGx test when the payer's WTP was below $Can3500 per QALY. When the payer's WTP exceeded $Can3500 per QALY, over 52% of simulations favored the strategy with the PGx test. This number reached 90% when the payer's WTP was $Can12,000 per QALY.
Scenario Analyses
As the performance parameters of a future PGx test are unknown, we investigated the full range of possible FNR and FPR values. 
Discussion
We found that the strategy with a perfect PGx test to diagnose statin-induced myopathy is cost effective. Our results were consistent even when considering the full range of possible PGx test performance outcomes (FPR and FNR combinations) at payer WTP thresholds of $Can10,000 and $Can50,000 per QALY, which are well within the WTP threshold values reported for Canada [41] . Even at the lowest WTP threshold, the model generated positive INMB values for all test performance outcomes that would be considered for a valid diagnostic tool. Our findings are consistent with the previous economic evaluation we conducted using a Markov model approach [21] .
Consequences of False Negative and False Positive Pharmacogenomics Test Results
The consequences of false negative (FN) and false positive (FP) test results do not balance out. The benefit from the statin protection outweigh the extremely small risk of a rhabdomyolysis. For instance, based on the Canadian Cardiology Society Dyslipidemia Management Guidelines, primary prevention patients are considered at high CV risk when they have a 10-year Framingham Risk Score C 20%, which corresponds to a C 2.2% annual probability of having a CVE [16] . This CVE risk is much higher than the risk of rhabdomyolysis. Rallidis et al. [7] reported that the rate of rhabdomyolysis was 3.2 per 100,000 person-years, but most studies report rates of around 10 per 100,000 person-years [42, 43] . These estimates correspond to an annual risk of rhabdomyolysis of 0.003-0.01%. Furthermore, rhabdomyolysis is often diagnosed early before it leads to renal damage and, therefore, does not require hospitalization.
Our scenario analysis captures this asymmetry in consequences. Although increasing the FNR and FPR rates simultaneously creates a decreasing trend in the economic value of the PGx test, we found that independently increasing the proportion of FN results does not have the same economic impact as independently increasing the proportion of FP results. For any level of FNR, the economic value of the PGx test for the payer decreases as the FPR increases. This is the case for any payer WTP threshold. However, the reverse does not hold true when independently increasing the proportion of FN results, holding FPR constant. In this latter situation, the economic value of the PGx test depends on the payer's WTP. At lower payer WTP thresholds (\ $Can20,000 per QALY), the economic value of the PGx test decreases as the FNR increases. At higher payer WTP thresholds, the value of the PGx test increases as the FNR increases as patients continue to benefit from statin protection.
Patients inadequately interrupting their statin therapy may represent an economic loss for payers. As explained by Cardinal et al. [44] , in preventive health strategies, patients who interrupt their treatment before they incur any benefit represent a resource inefficiency. As can be seen in the study from Pedersen et al. [22] , the statin benefit materializes after 1.5 years of statin treatment when compared with placebo.
Furthermore, the development of an accurate PGx test would be a useful tool for physicians and pharmacists to help maintain patients on continuous statin therapy. Many studies highlighted the poor adherence to and persistence of statin therapy [45] [46] [47] [48] . Wouters et al. [49] reported that among 229 patients, 40-70% doubted the need for statin therapy and lacked knowledge about its efficacy, while 20-35% worried about joint and muscle adverse effects [49] .
Strengths
Our DES model has several strengths, such as the use of estimated all-cause mortality and CVE risk survival curves obtained from the literature. This allowed us to conduct a DES model without access to patient-level data. With the DES approach, we were able to simulate patient characteristics and follow their history within the model. In contrast, this was not possible with the previous Markov model approach, which had limited memory [21] . Furthermore, the model design was not limited by the lack of 'real-world' PGx test parameters. We assessed the economic benefit across the full range of FNR and FPR test performance outcomes, providing a broad understanding of the expected value of such a test and allowing for the flexibility to analyze an imperfect test environment. Even if we had the true PGx test parameters, we would argue that analyzing the complete range of FPRs and FNRs is essential. Even with a perfect test (i.e., FPR and FNR = 0%), physician and patient responses to the test results influence treatment outcomes. Despite a perfect PGx test result indicating the absence of statin-induced myopathy, if physicians recommend interrupting the statin therapy, or if patients decide to ignore their physician's recommendations (i.e., statin non-adherence), this would be equivalent to an environment with an imperfect PGx test (i.e., FPR[ 0% and FNR = 0%). The extreme result would be a situation where all patients without statin-induced myopathy interrupted their statin therapy even though the PGx test result indicated they should continue. This would be equivalent to a PGx test with an FPR of 100%. Thus, this broad interpretation of test parameters encompasses statin non-adherence. As such, conducting the economic evaluation using the complete range of test parameters provides essential information to payers on the consequences of FN and FP test results.
Limitations
There are many uncertainties surrounding the incidence of severe statin-induced rhabdomyolysis and its associated disutility. An increase in the rate of severe rhabdomyolysis would increase the value of the PGx test. Our model simulates a secondary prevention population and results are not generalizable to all patients on statin therapy, such as those receiving statins for primary prevention of CV disease.
The model-predicted survival curves were limited to data that could be extracted from the published figures and the population characteristics underlying those figures. For instance, the study from Smolina et al. [26] allowed us to derive age group-/gender-specific survival curves, which were not available in other studies. To address these limitations, we explored the uncertainties by applying multipliers varying ± 20% to each survival curve in the DSA and PSA.
The strategy 'without the PGx test' may be seen as limiting as we assumed that all physicians and pharmacists will recommend discontinuing statin therapy when patients experience MSP. Regardless of their physician's or pharmacist's recommendations, as suggested by the literature on statin adherence, a significant proportion of patients will interrupt their statin therapy, leading to the same outcome [45, [47] [48] [49] .
Conclusion
We found that a PGx test strategy favoring patients staying on statin therapy is cost effective even if patients maintained on treatment are at risk of rhabdomyolysis. These results are explained by the fact that, in patients at high CV risk, statins can effectively reduce the CV risk, outweighing the risk of rhabdomyolysis. These results are consistent with our previous Markov model from a payer's perspective, even though the Markov model used different data sources for capturing CV risk and higher statin efficacy parameters due to the younger target population [21] .
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